Continue Monitoring Without Restarting Levothyroxine
If your thyroid function tests remain normal one year after stopping levothyroxine, you should continue monitoring without restarting medication. The decision to restart depends on whether TSH rises above 10 mIU/L or free T4 falls below the reference range during ongoing surveillance.
Monitoring Strategy
After discontinuing levothyroxine with currently normal thyroid function, implement the following surveillance protocol:
- Check TSH and free T4 at 6-month intervals for the first 1-2 years 1
- If values remain stable (TSH <10 mIU/L and free T4 within reference range), extend monitoring to annual testing 1
- More frequent testing (every 2-4 months) is warranted if TSH begins trending upward but remains <10 mIU/L 2
Recent high-quality evidence from 2026 demonstrates that 25.7% of adults aged 60+ successfully discontinued levothyroxine while maintaining adequate thyroid function at one year 3. Importantly, among those taking ≤50 mcg daily, the success rate increased to 63.6%, and thyroid-related quality of life showed no clinically relevant deterioration 3.
Criteria for Restarting Treatment
Restart levothyroxine only if:
- TSH rises above 10 mIU/L (regardless of free T4) 4, 5
- Free T4 falls below the reference range (even if TSH <10 mIU/L) 3, 5
- Symptomatic hypothyroidism develops with TSH 5-10 mIU/L and normal free T4 (consider trial of treatment) 4
The 2012 AACE/ATA guidelines support periodic re-evaluation once stable replacement has been achieved, with TSH testing at 6-12 month intervals 1. While these guidelines primarily address patients on treatment, they establish the principle that thyroid status requires ongoing assessment rather than automatic lifelong continuation.
Important Caveats
Special populations requiring immediate restart:
- Pregnant women or those planning pregnancy: Restart immediately if TSH is elevated, as even subclinical hypothyroidism may affect fetal neurodevelopment 4, 6. Check TSH as soon as pregnancy is confirmed and maintain in trimester-specific reference ranges 6
- History of thyroid cancer: These patients require TSH suppression therapy and should not discontinue without oncologic consultation 6
- Post-thyroidectomy or radioiodine ablation: These patients typically have minimal residual thyroid function and will likely require lifelong replacement 1
Watch for gradual deterioration: A 2017 pediatric study found that TSH >10 mIU/L at initial diagnosis predicted treatment need after discontinuation 5. If your original TSH at diagnosis was very high, remain vigilant for recurrence.
Age considerations: Thyroid hormone requirements decrease with age, and elderly patients often require 20-25% less levothyroxine per kilogram than younger patients 1. This physiologic change supports re-evaluation in older adults.
Clinical Context
The FDA labeling emphasizes that levothyroxine has a narrow therapeutic index, and both overtreatment and undertreatment carry risks 6. Overtreatment increases cardiovascular events (particularly atrial fibrillation in elderly), decreases bone mineral density in postmenopausal women, and may precipitate angina 6. Therefore, continuing unnecessary treatment poses real harm.
A 2025 pilot RCT showed that levothyroxine discontinuation in subclinical hypothyroidism was well-tolerated with minimal adverse events and no significant difference in quality of life measures at 6 months 7. Only 2 of 24 patients in the placebo group required treatment restart 7.
The key principle: Normal thyroid function one year off medication suggests your thyroid has adequate endogenous function. Continue surveillance rather than empirically restarting treatment, as you may be among the substantial proportion who no longer require lifelong therapy 3, 5, 7.